MarketCap
Facebook
X
Telegram
Relmada Therapeutics Balance Sheet 2025-2004 | RLMD
Brief balance sheet overview of Relmada Therapeutics
The comparison uses five available annual reports from the 2021–2025 interval.
Assets declined from $223.3 million to $94 million, or -57.9%. The contraction calls for context such as disposals, restructuring or weaker operations.
Asset and liability trends were close, at -57.9% and -50.3%. Expansion did not materially reshape funding sources.
Equity accounts for 92% of assets. Against the initial 93.3%, the capital position looks resilient.
Cash equals 3.7% of the balance sheet, compared with 19.9% five periods ago. This is the readily available cushion.
The balance sheet carries negative retained earnings of -$698.3 million. The figure may result from accumulated losses or an active capital return policy.
What the balance sheet shows
Relmada Therapeutics's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet Relmada Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | - | -2.5 M | -8.85 M | 703 K | -1.43 M | -8.23 M | -22.2 M | -25.5 M | -15.3 K | -8.95 K | - | - | - | - | - | - | - | - |
Long Term Debt |
- | - | - | - | - | - | - | 2.66 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | 2.66 M | - | 141 K | - | 100 K | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
6.43 M | 10.3 M | 12.2 M | 12.5 M | 15.1 M | 12.6 M | 1.46 M | 5.9 M | 1.38 M | 3.06 M | 15.6 M | 26.8 M | 21.5 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
7.49 M | 10.3 M | 12.2 M | 12.5 M | 15.1 M | 12.6 M | 2.61 M | 8.56 M | 1.38 M | 3.2 M | 15.6 M | 26.9 M | 33.7 K | 7 K | - | - | - | - | - | - | - | - |
Retained Earnings |
-698 M | -641 M | -561 M | -462 M | -305 M | -179 M | -112 M | -94.3 M | -85.4 M | -79.1 M | -76.1 M | -55.3 M | -57.2 K | -12.1 K | - | - | - | - | - | - | - | - |
Total Assets |
94 M | 45.8 M | 97.6 M | 153 M | 223 M | 118 M | 10.2 M | 3.05 M | 2.84 M | 10.2 M | 24.4 M | 25.8 M | 20 K | 18.4 K | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
3.5 M | 3.86 M | 4.09 M | 5.4 M | 44.4 M | 2.5 M | 36.3 M | 2.43 M | 1.71 M | 8.5 M | 22.5 M | 25.6 M | 3.52 M | 1.77 M | 21.9 K | - | - | - | - | - | - | - |
Book Value |
86.5 M | 35.5 M | 85.4 M | 140 M | 208 M | 106 M | 7.61 M | -5.51 M | 1.46 M | 7.04 M | 8.81 M | -1.11 M | -13.7 K | 11.4 K | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
86.5 M | 35.5 M | 85.4 M | 140 M | 208 M | 106 M | 116 M | 1.43 M | 1.46 M | 7.04 M | 8.81 M | -1.11 M | -17.9 M | -3.71 M | -2.84 M | -2.11 M | -1.31 M | -188 K | 1.58 M | -2.85 M | -1.82 M | -806 K |
All numbers in USD currency
Quarterly Balance Sheet Relmada Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Liabilities |
12.5 M | 16.6 M | 5.41 M | 5.17 M | 5.24 M | 10.3 M | 8.1 M | - | 12.4 M | 12.2 M | - | - | 10.1 M | 12.5 M | - | - | 15.4 M | 15.1 M | - | - | - | 12.6 M | - | - | - | 1.46 M | 2.54 M | 2.61 M | 2.61 M | 1.86 M | 10.3 M | 8.56 M | 8.56 M | 5.85 M | 4.15 M | 1.38 M | 1.38 M | 1.55 M | 2.35 M | 3.2 M | 3.2 M | 4.84 M | 15.6 M | 15.6 M | 25.4 M | 28.2 M | 48.6 M | 26.9 M | 26.9 M | 21.6 M | - | - | - | 5.71 M | - | - | - | - | - | - | - |
Retained Earnings |
-730 M | -717 M | -678 M | -668 M | -658 M | -641 M | -622 M | -600 M | -583 M | -561 M | -536 M | -514 M | -488 M | -462 M | -424 M | -385 M | -345 M | -305 M | -271 M | -228 M | -202 M | -179 M | -179 M | -179 M | -179 M | -120 M | -120 M | -120 M | -120 M | -105 M | -97.7 M | -94.3 M | -94.3 M | -87.8 M | -86.4 M | -85.4 M | -85.4 M | -81.8 M | -80.7 M | -79.1 M | -79.1 M | -73.9 M | -71.5 M | -76.1 M | -76.1 M | -79.7 M | -55.3 M | -55.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
219 M | 235 M | 14.9 M | 21.1 M | 27.7 M | 45.8 M | 55.7 M | 71 M | 84.4 M | 97.6 M | 109 M | 122 M | 136 M | 153 M | 187 M | 216 M | 226 M | 223 M | 90.9 M | 111 M | 104 M | 118 M | 118 M | 118 M | 118 M | 117 M | 117 M | 117 M | 117 M | 3.3 M | 1.56 M | 3.05 M | 3.05 M | 6.57 M | 5.61 M | 2.84 M | 2.84 M | 6.23 M | 7.92 M | 10.2 M | 10.2 M | 16.6 M | 20.5 M | 24.4 M | 24.4 M | 32.8 M | 27.8 M | 25.8 M | 25.8 M | 3.63 M | 20 K | 4.73 K | 12.3 K | 1.99 M | 18.4 K | 18.4 K | - | - | - | - | - |
Cash and Cash Equivalents |
11.3 M | 9.78 M | 1.38 M | 1.35 M | 1.15 M | 3.86 M | 1.48 M | 2.09 M | 1.34 M | 4.09 M | 6.7 M | 14.5 M | 28.9 M | 5.4 M | 42.5 M | 37.3 M | 44.9 M | 44.4 M | 11.4 M | 4.67 M | 3.8 M | 2.5 M | 7.54 M | 2.5 M | 2.5 M | 36.3 M | 36.3 M | 36.3 M | 36.3 M | 2.43 M | 887 K | 2.43 M | 887 K | 5.94 M | 4.68 M | 5.94 M | 4.68 M | 4.71 M | 6.22 M | 4.71 M | 6.22 M | 15.1 M | 19.2 M | 15.1 M | 19.2 M | 31.4 M | 27.4 M | 31.4 M | 27.4 M | 3.52 M | 3.95 M | 1.56 M | 1.37 M | 1.77 M | 8.95 K | 8.95 K | 4.78 K | 21.9 K | 3.01 K | - | - |
Book Value |
207 M | 219 M | 9.47 M | 15.9 M | 22.4 M | 35.5 M | 47.6 M | - | 72 M | 85.4 M | - | - | 125 M | 140 M | 187 M | 216 M | 210 M | 208 M | 90.9 M | 111 M | 104 M | 106 M | 118 M | 118 M | 118 M | 116 M | 115 M | 115 M | 115 M | 1.43 M | -8.74 M | -5.51 M | -5.51 M | 721 K | 1.46 M | 1.46 M | 1.46 M | 4.67 M | 5.57 M | 7.04 M | 7.04 M | 11.8 M | 4.9 M | 8.81 M | -963 K | 4.59 M | -20.7 M | -1.11 M | -1.11 M | -17.9 M | 20 K | 4.73 K | 12.3 K | -3.71 M | 18.4 K | 18.4 K | - | - | - | - | - |
Total Shareholders Equity |
207 M | 219 M | 9.47 M | 15.9 M | 22.4 M | 35.5 M | 47.6 M | 61.5 M | 72 M | 85.4 M | 101 M | 111 M | 125 M | 140 M | 166 M | 197 M | 210 M | 208 M | 72.7 M | 96.9 M | 91.1 M | 106 M | 106 M | 106 M | 106 M | 116 M | 116 M | 116 M | 116 M | 1.43 M | 1.43 M | 1.43 M | -8.74 M | 721 K | 1.46 M | 721 K | 1.46 M | 4.67 M | 5.57 M | 7.04 M | 7.04 M | 11.8 M | 13.8 M | 8.81 M | 8.81 M | 4.59 M | -20.7 M | -1.11 M | -1.11 M | -17.9 M | -13.7 K | -21.3 K | -28 K | -3.71 M | 11.4 K | 11.4 K | - | -2.84 M | 9.91 K | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Relmada Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
Schweden
Irlanda
France
China
